Navigation Links
Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
Date:12/8/2008

Interim Data from a Phase 2 Clinical Trial in B-Precursor Acute Lymphoblastic Leukemia Show that Blinatumomab is Able to Eliminate Minimal Residual Disease

BETHESDA, Md., Dec. 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, yesterday presented first interim data from a phase 2 clinical trial of BiTE(R) antibody blinatumomab (MT103/MEDI-538) in patients with acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and destroy cancer cells. The presentation took place at the 50th annual meeting of the American Society of Hematology, held December 6 to 9 in San Francisco, CA.

The patients in this phase 2 clinical trial are in complete hematological remission following intense chemotherapy regimens, but retain ALL cancer cells in their bone marrow - so called minimal residual disease (MRD). Various reports have confirmed that ALL patients with MRD following chemotherapy have a significantly worse prognosis than patients without MRD. Interim results for the ongoing phase 2 clinical trial of blinatumomab for ALL find the BiTE antibody was able to eliminate MRD. Six patients have been enrolled so far in the trial. Four patients have concluded at least two cycles of therapy with blinatumomab. Three out of these four patients turned MRD-negative after the first treatment cycle. One patient achieved stable disease after the first treatment cycle and does not show signs of hematological relapse to date. Except for one patient with a port infection, no severe toxicities were recorded so far.

"Today patients with MRD-positive ALL after first line therapy have very few options for treatment, and a very
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
5. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
8. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
9. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. Promising Data ATIR Studies Presented by NIH Investigators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... YORK , Oct. 22, 2014 New ... in the in vitro diagnostic (IVD) test industry, especially ... Information. The healthcare market researcher listed more than 25 testing ... could be the future of IVD products. Kalorama details the ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Currently ... Sartorius, A & D Weighing, Rice Lake, and ... Semi-Micro Balance . The Sartorius CPA Semi-Micro Balance ... affordable high-quality, precise, and user-friendly laboratory balance. , ... laboratory equipment, their laboratory balances are well known ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... DIEGO -- In the Sept 9, 2010 issue of ... of concept studies that show its proprietary compound, NGP ... Alzheimer,s disease (AD) in a transgenic mouse model. ... the gamma secretase modulator (GSM) compound from NGP, the ...
... GAITHERSBURG, Md. Using a one-of-a-kind instrument designed and ... (NIST), an international team of researchers have "unveiled" a ... in graphene can split up into an unexpected and ... low temperatures and extremely high magnetic fields. Published in ...
... THE WOODLANDS, Texas, Sept. 9 Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... president and chief executive officer, will present at the ... 16, 2010 at 9:10 a.m. Eastern Time. ...
Cached Biology Technology:Neurogenetic studies show proprietary compound reduces brain plaques linked to Alzheimer's 2NIST researchers hear puzzling new physics from graphene quartet's quantum harmonies 2NIST researchers hear puzzling new physics from graphene quartet's quantum harmonies 3Lexicon to Present at Stifel Nicolaus Healthcare Conference 2
(Date:10/16/2014)... and Mary,s Virginia Institute of Marine Science have ... Protection Agency to identify the streams and wetlands ... tools to help local governments and citizens conserve ... on a dataset of tidal-marsh observations first gathered ... this historical baseline can today,s researchers accurately map ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... weekend warriors: the simple act of exercise and not ... a new University of Florida study finds. People ... gaining strength or boosting cardiovascular fitness feel just as ... said Heather Hausenblas, a UF exercise psychologist. Her study ...
... sees the launch of Ensembl Plants a ... by the European Molecular Biology Laboratory,s European ... Spring Harbor Laboratory, USA. Ensembl Plants allows researchers ... genome-scale experiments in different plant species. By pinpointing ...
... disease and other diet related health problems received a 4 ... projects. The projects, taking place in universities and research institutes ... publicly-funded Research Councils and 15 companies. This means the research ... in our society but in a way that the food ...
Cached Biology News:UF study: Exercise improves body image for fit and unfit alike 2UF study: Exercise improves body image for fit and unfit alike 3New portal for plant genomics will support research into improved crops 2Public sector and industry unite to attack obesity and heart disease 2
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Rabbit polyclonal to HMGB1 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 3146 SwissProtID: P09429...
Pooled normal sreum with 0.1% sodium azide as preservative...
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Biology Products: